ABSTRACT
Polysaccharide-protein conjugate vaccines are new tools for the prevention of serious disease caused by encapsulated bacteria. Conjugate vaccines to prevent disease caused by Haemophilus influenzae type b (Hib) and serogroup C meningococcus (SCM) have already been introduced into routine national immunization programs. In this chapter, we review development and implementation of these vaccines, and present data from countries demonstrating their striking impact.
